These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 37736808

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Harsini S, Martineau P, Plaha S, Saprunoff H, Chen C, Bishop J, Tyldesley S, Wilson D, Bénard F.
    Cancer Imaging; 2024 Aug 30; 24(1):117. PubMed ID: 39210431
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis.
    Spohn SKB, Farolfi A, Schandeler S, Vogel MME, Ruf J, Mix M, Kirste S, Ceci F, Fanti S, Lanzafame H, Serani F, Gratzke C, Sigle A, Combs SE, Bernhardt D, Gschwend JE, Buchner JA, Trapp C, Belka C, Bartenstein P, Unterrainer L, Unterrainer M, Eiber M, Nekolla SG, Schiller K, Grosu AL, Schmidt-Hegemann NS, Zamboglou C, Peeken JC.
    Eur J Nucl Med Mol Imaging; 2022 Dec 30; 50(1):218-227. PubMed ID: 35984452
    [Abstract] [Full Text] [Related]

  • 9. A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study.
    Janbain A, Farolfi A, Guenegou-Arnoux A, Romengas L, Scharl S, Fanti S, Serani F, Peeken JC, Katsahian S, Strouthos I, Ferentinos K, Koerber SA, Vogel ME, Combs SE, Vrachimis A, Morganti AG, Spohn SK, Grosu AL, Ceci F, Henkenberens C, Kroeze SG, Guckenberger M, Belka C, Bartenstein P, Hruby G, Emmett L, Omerieh AA, Schmidt-Hegemann NS, Mose L, Aebersold DM, Zamboglou C, Wiegel T, Shelan M.
    JMIR Cancer; 2024 Sep 20; 10():e60323. PubMed ID: 39303279
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.
    Mazzone E, Gandaglia G, Robesti D, Rajwa P, Gomez Rivas J, Ibáñez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler WP, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Moreno Sierra J, Porpiglia F, Picchio M, Chiti A, van den Bergh R, Shariat SF, Montorsi F, Briganti A.
    Eur Urol Oncol; 2024 Apr 20; 7(2):231-240. PubMed ID: 37689506
    [Abstract] [Full Text] [Related]

  • 13. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.
    Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Lanzafame H, Giuseppe Morganti A, Trapp C, Koerber SA, Debus J, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Ruf J, Grosu AL, Ceci F, Fendler WP, Bartenstein P, Kroeze SGC, Guckenberger M, Krafcsik M, Klopscheck C, Fanti S, Hruby G, Emmett L, Belka C, Stief C, Schmidt-Hegemann NS, Henkenberens C, Mayer B, Miksch J, Shelan M, Aebersold DM, Thamm R, Wiegel T.
    Radiother Oncol; 2023 Jul 20; 184():109678. PubMed ID: 37146766
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
    Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J.
    Eur Urol; 2024 Jul 20; 86(1):52-60. PubMed ID: 38290964
    [Abstract] [Full Text] [Related]

  • 16. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    Roberts MJ, Chatfield MD, Hruby G, Nandurkar R, Roach P, Watts JA, Cusick T, Kneebone A, Eade T, Ho B, Nguyen A, Tang C, McCarthy M, Francis R, Stricker P, Emmett L.
    BJU Int; 2022 Nov 20; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
    [Abstract] [Full Text] [Related]

  • 17. Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes.
    Ng M, Guerrieri M, Wong LM, Taubman K, Sutherland T, Benson A, Byrne G, Koschel S, Yap K, Starmans M, Ong G, Macleod C, Foo M, Chao M.
    J Nucl Med; 2022 Sep 20; 63(9):1343-1348. PubMed ID: 35058320
    [Abstract] [Full Text] [Related]

  • 18. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    Roberts MJ, Conduit C, Davis ID, Effeney RM, Williams S, Martin JM, Hofman MS, Hruby G, Eapen R, Gianacas C, Papa N, Lourenço RA, Dhillon HM, Allen R, Fontela A, Kaur B, Emmett L, Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
    BJU Int; 2024 Feb 20; 133 Suppl 3():39-47. PubMed ID: 37604702
    [Abstract] [Full Text] [Related]

  • 19. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.
    Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.
    J Nucl Med; 2018 Feb 20; 59(2):230-237. PubMed ID: 29123013
    [Abstract] [Full Text] [Related]

  • 20. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.
    Lee EE, Singh T, Hu C, Han M, Deville CJ, Halthore A, Greco S, Tran P, DeWeese T, Song DY.
    Prostate; 2023 Feb 20; 83(2):190-197. PubMed ID: 36316967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.